| Date Filed | Type | Description |
| 04/30/2019 |
GN
| Rigrodsky & Long, P.A. Files Class Action Suit Against GTx, Inc. |
| 04/15/2019 |
GN
| GTx (GTXI) Merger Class Action Lawsuit: Halper Sadeh LLP Announces Filing of Shareholder Class Action Lawsuit Against GTx, Inc. Concerning its Proposed Merger With Oncternal Therapeutics, Inc. – GTXI |
| 03/20/2019 |
GN
| Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating the Boards of Directors of Clementia, Multi-Color, and GTx on Behalf of Stockholders and Encourages Investors to Contact the Firm |
| 03/07/2019 |
GN
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of GTx, Inc. to Oncternal Therapeutics, Inc. is Fair to Shareholders |
| 08/20/2018 |
GN
| Recent Analysis Shows Ferroglobe, AXT, ChemoCentryx, RedHill Biopharma, GTx, and Achillion Pharmaceuticals Market Influences — Renewed Outlook, Key Drivers of Growth |
| 06/05/2018 |
GN
| Detailed Research: Economic Perspectives on First Mid-Illinois Bancshares, GTx, Ferroglobe, SunOpta, Bandwidth, and Carbonite — What Drives Growth in Today's Competitive Landscape |
| 04/13/2018 |
GN
| Research Report Identifies Third Point Reinsurance, GTx, pdvWireless, ACM Research, Reading International, and Canadian National Railway with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement |
| 03/12/2018 |
BW
| GTx Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial Results |
| 11/14/2017 |
BW
| GTx Provides Corporate Update and Reports Third Quarter 2017 Financial Results |
| 09/25/2017 |
BW
| GTx Announces Webcast of Corporate Presentation at the 2017 Cantor Fitzgerald Global Healthcare Conference |
| 08/14/2017 |
BW
| GTx Provides Corporate Update and Reports Second Quarter 2017 Financial Results |
| 05/15/2017 |
BW
| GTx Provides Corporate Update and Reports First Quarter 2017 Financial Results |
| 03/15/2017 |
BW
| GTx Provides Corporate Update and Reports Fourth Quarter and Year-End 2016 Financial Results |
| 03/07/2017 |
BW
| GTx, Inc. to Report Fourth Quarter and Full Year 2016 Financial Results on March 15, 2017 |
| 08/11/2011 |
BW
| GTx Announces Webcast of Corporate Presentation at the 2011 Wedbush Life Sciences Conference |
| 06/30/2011 |
BW
| GTx Announces Upcoming Presentations of Effects of Ostarine™ in Non-Small Cell Lung Cancer Patients at World Conference on Lung Cancer |
| 06/20/2011 |
BW
| GTx Initiates Phase IIb Clinical Trial Evaluating Oral Capesaris™ Tablets Versus Lupron Depot® for First Line Treatment of Advanced Prostate Cancer |
| 06/06/2011 |
BW
| GTx Announces Agreement with FDA on Phase III Clinical Development Plan Evaluating Ostarine™ (GTx-024) for the Prevention and Treatment of Muscle Wasting in Patients with Non-Small Cell Lung Cancer |
| 06/01/2011 |
BW
| GTx Announces Webcast of Corporate Presentation at the Jefferies 2011 Global Healthcare Conference |
| 05/18/2011 |
BW
| GTx Announces ASCO Presentations Highlighting Effects of Ostarine™ on Physical Function and Survival in Patients with Non-Small Cell Lung Cancer |
| 05/17/2011 |
BW
| GTx Presents Preclinical Study Results Demonstrating That Capesaris™ (GTx-758) Chronic Treatment Does Not Cause Gynecomastia in Male Primates |
| 05/09/2011 |
BW
| GTx Provides Corporate Update and Reports First Quarter 2011 Financial Results |
| 05/02/2011 |
BW
| GTx, Inc. To Host First Quarter 2011 Financial Results Conference Call and Webcast |
| 12/13/2010 |
BW
| GTx Presents Results of the Capesaris™ (GTx-758) Phase II Proof of Concept Pharmacokinetic-Pharmacodynamic Clinical Trial |
| 11/15/2010 |
BW
| GTx Presents Preclinical Studies of GTx-758, a Selective Estrogen Receptor Alpha Agonist for First Line Treatment of Advanced Prostate Cancer, and GTx-230, an Orally Available Tubulin Antagonist for Cancer Refractory to Taxane and Vinca Alkaloid Therapy |
| 11/11/2010 |
BW
| GTx Announces Corporate Presentation at the Lazard Capital Markets Annual Healthcare Conference |
| 11/09/2010 |
BW
| GTx, Inc. Reports Third Quarter 2010 Corporate Results |
| 11/08/2010 |
BW
| GTx Appoints Dr. Barry Furr to the Board of Directors |
| 11/03/2010 |
BW
| GTx Awarded $1.2 Million in Grants for Qualifying Therapeutic Discovery Projects |
| 10/27/2010 |
BW
| GTx Announces Pricing of Public Offering of Common Stock |
| 10/26/2010 |
BW
| GTx Announces Proposed Public Offering of Common Stock |
| 09/16/2010 |
BW
| GTx Announces Corporate Presentation at the UBS Global Life Sciences Conference |
| 09/15/2010 |
BW
| GTx Announces That GTx-758, a Novel Oral Selective Estrogen Receptor Alpha Agonist Being Developed to Treat Advanced Prostate Cancer, Induced Medical Castration in a Phase II PK/PD Clinical Trial |